Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Avadomide with Food and CYP Modulators
NCT03340662Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Nov 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of avadomide in diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM) (4 arms), sponsored by Celgene Corporation. Primary endpoints: Maximum Plasma Concentration at 1 month and Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity at 1 month. Started Nov 2017; status: completed.
02
Drugs
avadomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03340662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03340662.